Amivantamab Before Surgery for EGFR-Mutated Non-Small Cell Lung Cancer
Tests amivantamab with lazertinib or chemotherapy before surgery for EGFR-mutated lung cancer.
Plain-language title generated from the registry record
Registry title: A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Key facts
- Where
- Beijing, Cheng Du Shi, Chengdu, Guangzhou, Jinan, Shanghai, and Tianjin, ChinaSee the 7 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-squamous non-small cell lung cancer (NSCLC) that can be removed by surgery and has an EGFR mutation. They receive amivantamab with lazertinib or with chemotherapy before surgery.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- Non-squamous NSCLC, Stage II-IIIB N2, that can be completely removed by surgery.
- Earlier treatment
- People cannot have had any earlier drug treatment for NSCLC, such as EGFR-TKI therapy, chemotherapy, biologic therapy, immunotherapy or an investigational drug.
- Biomarker or test result
- An EGFR mutation (Exon 19del or Exon 21 L858R).
Main reasons for not taking part
- Uncontrolled illness
- Past or current interstitial lung disease or pneumonitis
- Known allergy or intolerance to the study drugs or their ingredients
- Other driver mutations such as ALK, MET, HER2, ROS1, NTRK, BRAF, RET or KRAS
- Any earlier systemic anti-cancer treatment for NSCLC
Read by machine on 9 November 2026.
Where in China
- Beijing Cancer Hospital of Peking UniversityBeijing, ChinaTaking people
- Sichuan Cancer HospitalCheng Du Shi, ChinaTaking people
- West China Hospital，Sichuan UniversityChengdu, ChinaTaking people
- Guangdong Provincial People's HospitalGuangzhou, ChinaTaking people
- Shandong Cancer HospitalJinan, ChinaTaking people
- Shanghai Pulmonary HospitalShanghai, ChinaTaking people
- Tianjin Chest HospitalTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Janssen Research & Development, LLC
- Trial code
- NCT07586202
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal growth factor receptor (EGFR) mutated, Stage II-IIIB non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. NSCLC may occur due to mutations (changes) in many genes, including EGFR.Read full original descriptionShow less
A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer
The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal growth factor receptor (EGFR) mutated, Stage II-IIIB non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. NSCLC may occur due to mutations (changes) in many genes, including EGFR.
Inclusion: Participant must have histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC) with completely resectable Stage II-IIIB N2 disease; Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a multidisciplinary team evaluation; Participant must consent to a screening biopsy, if clinically feasible, if no adequate tumor tissue is available for a baseline sample; Participant may have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s). Prior or concurrent second malignancies must be reviewed and agreed to with the medical monitor; Have an eastern cooperative oncology group (ECOG) performance status of 0 or 1.
Exclusion: History of uncontrolled illness; Medical history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, or has current interstitial lung disease (ILD)/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening; Suspected or known allergies, hypersensitivity, or intolerance to excipients of: the combination of amivantamab and lazertinib or carboplatin and pemetrexed; Presence of primary driver mutations (anaplastic lymphoma kinase [ALK], mesenchymal-epithelial transition [MET], human epidermal growth factor receptor 2 [HER2], proto-oncogene tyrosine-protein kinase ROS [ROS1], neurotrophic tyrosine receptor kinase [NTRK], B-Raf proto-oncogene [BRAF], REarranged during transfection [RET], or kirsten rat sarcoma viral oncogene homolog [KRAS]) , besides EGFR Exon 19del or Exon 21 L858R mutations, as determined by local genomic testing; Prior treatment with any systemic anti-cancer therapy for NSCLC including EGFR-tyrosine kinase inhibitor (TKI) therapy, chemotherapy, biologic therapy, immunotherapy, or any investigational drug.